Understanding how SARS-CoV-2 Spike proteins interact with antibodies
Official title: In situ structures of SARS-CoV-2 Spike fusion intermediates and Spike-antibody-Fc receptor complexes
Funded at Yale University · NIH-11002280 · Data updated 2026-11-12
This study is looking at a part of the virus that causes COVID-19 to understand how it helps the virus enter our cells, with the hope of finding new ways to create better treatments and vaccines for everyone.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $33,952 |
| NIH project number | 5F31AI176650-02 |
| Project ID | NIH-11002280 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have been infected with SARS-CoV-2 or are at risk of infection, particularly those with underlying health conditions.
✕Less likely to help
Patients who have not been exposed to SARS-CoV-2 or those with no risk factors for infection may not benefit from this research.
What this research studies
This research investigates the structures of the SARS-CoV-2 Spike protein, particularly focusing on its S2 domain, which is crucial for the virus's ability to enter human cells. By examining how this protein changes shape during the infection process, the study aims to identify potential targets for new antiviral therapies. The research utilizes advanced molecular techniques to visualize these interactions in their natural environment, which could lead to the development of more effective treatments against COVID-19 variants. Patients may benefit from insights that could enhance vaccine efficacy and antibody therapies.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments and vaccines against COVID-19 variants.
How similar studies have gone: Other research has shown success in targeting conserved viral structures for vaccine development, indicating a promising approach in this area.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Grunst, Michael William — Yale University
- Study coordinator: Grunst, Michael William
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.